Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

Chia Siang Kow, Syed Tabish Razi Zaidi, Syed Shahzad Hasan

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalAmerican Journal of Cardiovascular Drugs
Issue number3
Early online date13 Apr 2020
Publication statusPublished - 1 Jun 2020


Dive into the research topics of 'Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19'. Together they form a unique fingerprint.

Cite this